Schedule III Changes the Math: The R&D Tax Credit Is Open to Medical Cannabis for the First Time

Every article about rescheduling says the same thing: medical cannabis operators can finally deduct rent, payroll and marketing. That is true, and it is half the story. Section 280E of the Internal Revenue Code denied deductions and credits, and the credit that matters most to the production side of this industry is one that medical marijuana cultivators, extractors and product manufacturers have never been allowed to claim: the federal research and development tax credit under Section 41.

In every other agricultural, food and pharmaceutical business, the work of developing a plant line, tuning an extraction process or formulating a consistent-dose product earns a federal credit worth six to ten percent of the qualified spend. In medical cannabis it earned nothing, so nobody built the habit of tracking it, and most operators do not know it exists. On April 22, 2026, medical cannabis (medical marijuana) produced, distributed or dispensed under a qualifying state license became a Schedule III controlled substance, and Section 280E does not reach Schedule III. The credit is open, and under the transition rule Treasury described the next day it is open for the whole of 2026.

This post explains what was rescheduled and what was not, why the change unlocks the R&D credit, which medical cannabis activities are likely to qualify, what dual-license operators need to do differently, and how to prepare a 2026 claim. It is written for operators and their CPAs, and it stays inside what the order and the tax code actually say.

What Changed on April 22, 2026?

The Acting Attorney General signed a final order on April 22, 2026, effective that day and published in the Federal Register on April 28, placing two categories of cannabis in Schedule III: drug products containing cannabis approved by the Food and Drug Administration, and cannabis manufactured, distributed or dispensed under a qualifying state medical license. The Justice Department announced it on April 23, and Treasury and the IRS issued their own release the same day saying guidance is coming and that rescheduling applies for the full taxable year that includes the effective date.

Everything else stayed where it was. Adult-use (recreational) cannabis, unlicensed bulk cannabis and synthetic cannabinoids remain in Schedule I. A separate Drug Enforcement Administration proceeding on rescheduling all cannabis to Schedule III held an eleven-day hearing that concluded on July 15, 2026, with post-hearing briefs due August 17, 2026. As of this writing there is no final decision in that proceeding.

The practical result is a two-tier market. An operator whose entire business runs under a state medical license is outside Section 280E for all of 2026 if it files on a calendar year. An operator with both medical and adult-use licenses is outside Section 280E for the medical side only. An adult-use operator is exactly where it was.

Why Does Schedule III End Section 280E for Medical Operators?

The statute is short and its reach was total. Because cannabis sat in Schedule I, a licensed medical dispensary or grower could not deduct rent, payroll, marketing or professional fees against income, and could not claim any federal credit, including the R&D credit under Section 41. Courts applied the rule consistently, and operators were left reducing cost of goods sold as their only relief.

Moving the product to Schedule III removes the trigger. For the taxable year that includes April 22, 2026, a licensed medical operator's ordinary and necessary expenses are deductible under the normal rules, and the federal credits that every other manufacturer, farmer and lab uses are open to it. The R&D credit is the one with the most immediate value for the production side of the industry, because cultivation, extraction and formulation are experimental by nature and generate the kind of costs the credit rewards.

Two cautions belong here. The first return the change affects without any contingency is the 2026 return, and under Treasury's transition rule a calendar-year operator claims the full year, not the part after April. And the order encourages Treasury to consider relief for years in which a licensee operated under a state medical program; Treasury's April 23 release said nothing about those years, and the IRS's most recent Tax Court brief on the subject, filed in March before the order, still argued that 280E applies to every year cannabis sat in Schedule I. We are monitoring that. Because the refund window under 26 U.S.C. Section 6511 closes year by year whether or not Treasury acts, operators are filing protective refund claims to preserve their open years, covering both the deductions and the credit; a 2022 return filed on extension closes October 16, 2026. A 2026 study does not exclude a taxpayer from that relief when it is issued. We cover the mechanics in our post on the October 16 deadline for medical cannabis operators.

Which Medical Cannabis Activities Qualify for the R&D Credit?

Any medical cannabis work that meets the Section 41 four-part test qualifies: it pursues a new or improved product or process, faces technical uncertainty at the outset, resolves that uncertainty through experimentation, and relies on the hard sciences.

That is the same test the IRS applies to pharmaceutical, food and agricultural research. Applied to a licensed medical operation, the activities most likely to qualify are these.

Cultivation science. Developing and stabilizing plant lines for target cannabinoid ratios, including high-CBD, balanced and minor-cannabinoid lines such as CBG and THCV. Phenotype hunting, tissue culture and replicated grow trials that test whether a line holds its profile across harvests are experimentation in the statutory sense.

Grow-environment optimization. Trials on LED spectra, photoperiods, CO2 enrichment, fertigation recipes, substrates and integrated pest management, where yield, potency and terpene expression are measured against each change. The uncertainty is real because the interaction between light, nutrients and genetics is not predictable from published data.

Extraction and purification. Iterating CO2, ethanol, hydrocarbon or solventless processes and the downstream winterization, distillation and chromatography steps to hit purity and terpene-retention targets while removing residual solvents. Process parameters that work at bench scale often fail at production scale, which is exactly the uncertainty the credit is designed to reward resolving.

Dosage form and formulation development. Building precision-dosed products for patients, including tinctures, capsules, sublingual strips, suppositories, transdermals and edibles, and testing homogeneity, stability, onset and shelf life through formulation iterations.

Analytical method development. Developing and validating potency, contaminant, residual-solvent and heavy-metal methods for difficult matrices such as gummies, beverages and oils, and building in-process controls that keep batches inside state specifications.

Scale-up and process validation. Moving a formulation or extraction from pilot to commercial production, redesigning batch records and qualifying equipment when the outcome at scale is not known in advance.

Software. Seed-to-sale, batch genealogy and testing-integration systems qualify when the technical approach to data integrity or interoperability with state systems is unresolved at the start.

Routine cultivation, harvest, trim and packaging using settled methods do not qualify. Neither does batch-release compliance testing with no method development, dispensary operations, marketing or general administration. For the four-part test in more detail, see our guide to R&D tax credit eligibility.

What Counts as a Qualified Research Expense?

Wages for staff who perform, directly supervise or directly support qualified research; supplies used or consumed in the research; 65 percent of most contract research; and software or cloud costs used directly in experimentation.

In a medical cannabis operation, wages usually dominate. Founders and executives count for the hours they spend directing experiments, not for running the business. Contract research counts as long as you keep substantial rights to the results and bear the financial risk.

Federal credits typically run 6 to 10 percent of qualified research expenses under the regular or alternative simplified method. Companies under $5 million in gross receipts and within five years of their first revenue can apply up to $500,000 of the credit per year against payroll tax, which matters for growers and formulators that are not yet profitable. Many states offer their own R&D credits on top, and several decoupled from Section 280E for state income tax purposes years ago, so the state picture may be better than the federal one for prior years.

Use the R&D tax credit calculator for a first estimate, and read the Section 174 explainer for how immediate expensing of domestic research under the One Big Beautiful Bill Act interacts with the credit.

What Should Dual-License Operators Do Differently?

Separate the medical business component from the adult-use business component, and claim the credit only on research attributable to the medical side.

This is the hardest part of the transition and the place where a claim is most likely to be challenged. Section 280E still applies to adult-use activity. If the same cultivation room, extraction line or formulation team serves both licenses, the research costs need an allocation method that an examiner will accept, tied to records that show which rooms, batches and SKUs were produced under the medical license.

The practical steps are a license map that ties every production area and product to a license, batch records that carry the license designation, time records by research project rather than by department, and a written allocation methodology adopted before the year closes rather than reconstructed afterward. Operators in medical-only states have a simpler path, but they still need the same research documentation as any other claimant.

How Do You Document a 2026 Medical Cannabis R&D Claim?

Keep, for every experimental project, the technical question you started with, the alternatives you tried, the trial data and what you learned, plus time records and contracts that show who did the work and who owns the results.

The IRS does not require a particular format, but it does look for contemporaneous evidence. In this industry the raw material already exists: trial plans, grow logs and harvest data by plant line and treatment, extraction and formulation batch records with the parameters tested, certificates of analysis for every trial batch, and lab and consultant contracts. The gap is usually the connective tissue, meaning the record that explains why a trial was run and what technical uncertainty it addressed, and the time tracking that ties people to projects.

Start now rather than at year end. The 2026 claim covers the full year for a calendar-year operator, and it is far easier to record which experiments ran and who ran them while the season is still going than to reconstruct it in March. The credit is claimed on Form 6765 with the 2026 return, with the business component detail the current form requires.

Strike prepares the study, the Form 6765 support and the examination defense on every engagement, on a contingency basis with no upfront fee. See our guide to R&D tax credit eligibility for the four-part test in more detail, or use the booking button above to walk through your operation with our team.

What About Hemp and CBD?

Nothing changed for compliant hemp and CBD. Section 280E never applied to them, and their research has qualified for the credit since the 2018 Farm Bill.

There is a separate development on that side of the plant. Section 781 of the fiscal 2026 appropriations act, signed November 12, 2025, narrows the federal definition of hemp to a total THC standard of 0.3 percent on a dry-weight basis, including THCA and delta-8, with finished cannabinoid products capped at 0.4 mg total THC per container. H.R. 6500, signed September 2, 2026, moved the effective date for naturally occurring cannabinoids to December 11, 2026; the November 12, 2026 date still applies to synthetic cannabinoids. Research on fiber, grain, non-intoxicating CBD and compliant formulations qualifies exactly as before. Products that fall outside the new definition after that date do not.

What Happens Next?

Three things to watch. First, the formal Treasury and IRS guidance announced on April 23 has not been published yet, and the announcement was silent on retrospective Section 280E relief. Second, the DEA's broader rescheduling proceeding is awaiting a decision after the July hearing; if it moves all cannabis to Schedule III, adult-use operators join the group that can claim. Third, states will continue to adjust their own conformity rules. We will update this post as each of those lands.

For licensed medical operators, the action is not to wait. Document the research that is happening now, adopt an allocation method if you hold both license types, and plan the 2026 return with the credit in it.

Official Sources

• Department of Justice press release, April 23, 2026
• Treasury and IRS press release, April 23, 2026, Schedule III transition rule
• CRS Legal Sidebar LSB11424, the April 22, 2026 final order (91 FR 22714)
• 26 U.S.C. section 280E, Cornell Law School LII
• 26 U.S.C. section 41, Cornell Law School LII
• 26 U.S.C. section 6511, Cornell Law School LII

Disclaimer: This article is for general informational purposes only and does not constitute tax, legal, or financial advice. Treasury has not issued guidance on prior years, and license structure, entity type and filing dates all affect outcomes. Confirm your position with a qualified tax professional before you file.

Work With Strike Tax Advisory

Strike Tax Advisory is an R&D tax credit specialist firm helping innovative businesses across manufacturing, agriculture, engineering, software, and other technical industries claim federal and state research credits.

For a state-licensed medical cannabis cultivator, extractor or manufacturer, our team will:

• Identify the 2026 research that meets the four-part test, project by project
• Build the license map and allocation method if you hold medical and adult-use licenses
• Prepare the R&D study and the Form 6765 support with your 2026 return
• Work with your CPA on protective claims for open prior years
• Stand behind the claim with examination defense